Illumina (ILMN) announced it has signed an agreement with Janssen Research & Development (JNJ). This collaboration will be the first relating to the development of Illumina’s novel molecular residual disease assay, a whole-genome sequencing multi-cancer research solution that detects circulating tumor DNA to better understand the persistence or recurrence of disease following clinical intervention.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ILMN:
- Illumina downgraded to Market Perform after 40% rally at TD Cowen
- Illumina downgraded to Market Perform from Outperform at TD Cowen
- Illumina put volume heavy and directionally bearish
- SHAREHOLDER ALERT: Potential Recovery for Illumina, Inc. (ILMN) Investors
- SomaLogic sent letter to stockholders on transaction with Standard BioTools